Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review (Q37792889)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 26, 2010

Language	Label	Description	Also known as
English	Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review	scientific article published on September 26, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review (English)

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

0 references

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

postmenopausal osteoporosis

1 reference

based on heuristic

inferred from title

author name string

S. J. Gallacher

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20872215

20 July 2024

T. Dixon

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20872215

20 July 2024

language of work or name

0 references

publication date

26 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

full work available at URL

http://link.springer.com/content/pdf/10.1007/s00223-010-9420-x.pdf

Portable Document Format

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

http://link.springer.com/article/10.1007/s00223-010-9420-x/fulltext.html

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

http://link.springer.com/content/pdf/10.1007/s00223-010-9420-x

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Calcified Tissue International

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

87

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

469-484

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells

1 reference

https://api.crossref.org/works/10.1007%2FS00223-010-9420-X

21 January 2018

Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).

1 reference

https://api.crossref.org/works/10.1007%2FS00223-010-9420-X

21 January 2018

Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy

1

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Bone mineral density thresholds for pharmacological intervention to prevent fractures

2

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.

3

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis

4

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

5

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Severely suppressed bone turnover: a potential complication of alendronate therapy

6

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Severely suppressed bone turnover and atypical skeletal fragility

7

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Bisphosphonate associated osteonecrosis of the jaw.

8

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Osteonecrosis of the jaw and bisphosphonates

9

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

10

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Thinking inside and outside the envelopes of bone: dedicated to PDD

11

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure

12

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Bisphosphonate mechanism of action

13

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

14

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation

15

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

16

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

17

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy

18

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window

19

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis

20

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis

21

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium

22

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide

23

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

24

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study.

25

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84

26

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

27

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study

29

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial

30

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women

31

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis

32

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

34

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

35

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Transmission of human herpesvirus 8 by blood transfusion

36

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

37

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

To stop or not to stop, that is the question

38

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Trabecular bone microarchitecture after alendronate treatment of osteoporotic women

39

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography

40

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate

41

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography

42

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

43

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.

44

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

45

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover

46

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography

47

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

48

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis

49

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women

50

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study

52

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate

53

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Spectroscopic markers of bone quality in alendronate-treated postmenopausal women

54

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment

55

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study

56

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Bone microdamage: a clinical perspective

57

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

58

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Evolving data about subtrochanteric fractures and bisphosphonates

59

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters

60

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis

61

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Rebalancing bone turnover in favour of formation with strontium ranelate: implications for bone strength.

62

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial

63

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide

64

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Strontium ranelate for preventing and treating postmenopausal osteoporosis

65

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

66

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate.

67

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization.

69

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

71

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate

72

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

73

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover

74

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis

75

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

76

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice

77

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment

78

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest

79

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.

80

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis

81

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Effects of teriparatide retreatment in osteoporotic men and women

82

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

84

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

85

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans

86

1 reference

10.1007/S00223-010-9420-X

https://api.crossref.org/works/10.1007/S00223-010-9420-X

20 July 2024

Identifiers

10.1007/S00223-010-9420-X

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37792889&oldid=2209083623"